IVP · As filed with the SEC
Inspire Veterinary Partners cash flow statement, by fiscal year
The statement as Inspire Veterinary Partners presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net loss | (14,264,261) | (14,792,886) | (4,911,926) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 1,337,723 | 1,252,539 | 595,627 |
| Amortization of debt issuance costs | 15,825 | 128,583 | 189,414 |
| Amortization of debt discount | 2,275,594 | 864,350 | 689,554 |
| Amortization of operating right of use assets | 329,878 | 162,298 | 13,958 |
| Stock-based compensation | 23,647 | — | — |
| Issuance of warrants to CEO | — | 2,701 | — |
| Issuance of class A common stock for services | 376,696 | 397,892 | 216,252 |
| Debt extinguishment loss | — | 16,105 | — |
| Loss on debt modification | 2,134,218 | 927,054 | — |
| Beneficial conversion feature | — | 4,137,261 | — |
| Issuance of class A common stock in connection with general release agreement | 20,000 | — | — |
| Issuance of Class A common stock and pre-funded warrants in connection with commitment shares | 600,000 | — | — |
| Bad debt provision | — | 123,513 | — |
| Gain on disposal of business | (467,049) | — | — |
| Impairment expense | 56,664 | — | — |
| Changes in operating assets and liabilities, net of effect of acquisitions: | |||
| Accounts receivable | (12,102) | (152,086) | — |
| Due from former owners | 32,519 | 237,364 | (233,898) |
| Inventory | 12,418 | 84,912 | (230,125) |
| Refundable income tax | 151,796 | 40,343 | — |
| Prepaid expenses and other current assets | (553,697) | (134,964) | (187,931) |
| Other assets | (41,102) | 16,561 | — |
| Accounts payable | (1,227,091) | 2,187,663 | 974,040 |
| Accrued expenses | (593,544) | 813,144 | 230,326 |
| Cumulative Series A preferred stock dividends payable | (92,322) | — | — |
| Operating lease liabilities | (121,676) | (133,119) | (3,600) |
| Net cash used in operating activities | (10,005,866) | (3,820,772) | (2,658,309) |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (237,983) | (383,729) | (134,971) |
| Purchase of intangible assets | — | — | (41,819) |
| Payment for acquisition of businesses | — | (1,485,800) | (14,511,804) |
| Advances for target acquisitions | — | — | 21,798 |
| Net cash used in investing activities | (237,983) | (1,869,529) | (14,666,796) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of class A common stock and warrants, net of issuance costs | 5,460,000 | 5,439,571 | — |
| Proceeds from issuance of class A common stock and pre-funded warrants, net of issuance costs | 5,227,039 | — | — |
| Repurchase and cancellation of the class B common stock | (650,000) | — | — |
| Net proceeds from loans payable | 1,981,585 | 2,038,531 | — |
| Payments on loans payable | (5,113,947) | (1,923,474) | — |
| Proceeds from issuance of convertible series A preferred stock | 200,000 | — | — |
| Proceeds from convertible note payable | 1,000,000 | — | 12,253,585 |
| Debt issuance costs | — | — | (260,611) |
| Payments on convertible note payable | (294,118) | — | — |
| Repayment of note payable | (1,121,981) | (329,620) | (494,034) |
| Proceeds from issuance of bridge notes | — | — | 2,600,000 |
| Proceeds from issuance of convertible debentures | — | 650,000 | 1,612,000 |
| Proceeds from exercise of warrants | 4,000,000 | — | — |
| Repayment of convertible debentures | (100,000) | (250,000) | — |
| Net cash provided by financing activities | 10,588,578 | 5,625,009 | 15,710,940 |
| Net increase (decrease) in Cash, cash equivalents and restricted cash | 344,729 | (65,292) | (1,614,165) |
| Cash, cash equivalents and restricted cash, beginning of period | 378,961 | 444,253 | 2,058,418 |
| Cash, cash equivalents and restricted cash, end of period | 723,690 | 378,961 | 444,253 |
| Supplemental Disclosure of Cash Flow Information | |||
| Interest payments during the year | 1,552,313 | 1,316,378 | 239,430 |
| Income tax refund | 151,796 | — | 192,139 |
| Noncash investing and financing activity | |||
| Series A Preferred Stock Dividend | 220,850 | 271,245 | — |
| Acquisition of assets through operating leases | 593,409 | 1,031,523 | 760,931 |
| Issuance of class A common stock for conversion of convertible notes payable | 1,357,143 | — | — |
| Issuance of common stock in connection with business acquisition | — | 400,000 | — |
| Issuance of convertible series A preferred stock due to conversion of bridge notes | — | 4,440,688 | — |
| Issuance of class A common stock due to conversion of convertible debentures | — | 4,414,317 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.